Globally, we have poor epidemiological data collection on new HIV diagnoses amongst transgender people, but survey data indicates that transgender people are disproportionately affected by HIV globally. Major PrEP trials have included low (or no) numbers of transgender people, and hence we have limited data on the effectiveness of PrEP in this priority population, but as clinicians we do need to advise our transgender patients about PrEP. When doing so, you could argue that the effectiveness of PrEP is dependent on adherence and on what type of sex a person has (e.g. receptive anal, insertive anal, receptive genital, insertive genital); it is not a product of their gender identity. Hence, if a trans man’s or trans woman’s risk of HIV is from receptive anal sex, then you could extrapolate from both the iPrEX and IPERGAY trials (which included mainly cis-MSM) to say that with good adherence both continuous daily PrEP and on-demand PrEP would provide excellent levels of HIV protection.